Oblique Therapeutics Announces Emission Details

Eminova Partners Corporate Finance AB is acting as financial advisor and MAQS Advokatbyrå AB as legal advisor to Oblique in connection with the emission. Eminova Fondkommission AB is acting as the issuing agent in connection with the emission.

For further information, please contact:

Anders Tidfors, CFO
Tel: 0702-295810
E-mail: anders.tidfors@obliquet.com

About Oblique Therapeutics

Oblique Therapeutics is a biotechnology company focused on developing new therapeutic methods for the treatment of serious diseases, particularly in pain management, as well as for other conditions. The company uses cutting-edge technology and innovative research methods to discover and develop new antibody-based drug candidates.

Important Information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade in securities in Oblique Therapeutics. No action has been taken and no measures will be taken to allow an offer to the public in any jurisdiction other than Sweden. Invitation to concerned persons to subscribe for convertibles will only take place through the prospectus that Oblique Therapeutics intends to publish before the subscription period in the issue begins. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (“The Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. A prospectus, corresponding to an EU growth prospectus, regarding the issue referred to in this press release will be prepared and published before the subscription period in the issue begins.

The information in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

No convertibles or other securities in Oblique Therapeutics have been registered, and no convertibles or other securities will be registered, under the United States Securities Act of 1933 (the “Securities Act”) or the securities laws of any state or other jurisdiction in the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with the securities laws of the relevant state or other jurisdiction in the United States. There is no intention to register any securities mentioned herein in the United States or to make a public offering of such securities in the United States.

This communication is distributed and directed only to persons in the United Kingdom who are (i) professional investors falling within Article 19(5) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities and other persons to whom this message may lawfully be addressed, who are covered by Article 49(2)(a)-(d) of the Order (all such persons together referred to as “Relevant Persons”). Persons who are not Relevant Persons must not act on or rely on the information in this communication. An investment or investment measure to which this communication relates is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.

Oblique Therapeutics has assessed that the Company conducts protected activities under the Act (2023:560) on the review of foreign direct investments (“FDI Act”). This means that investors who achieve a certain influence in the Company may need to notify investments in the Company to, and obtain approval from, the Swedish Inspectorate of Strategic Products (ISP) before such an investment can be implemented. Each investor should consult an independent legal advisor on any application of the FDI Act in connection with the issue for the individual investor.

This press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is only to describe the background to the issue and does not claim to be complete or exhaustive. No assurance shall be given in connection with the information in this press release regarding its accuracy or completeness. An investment decision to acquire or subscribe for convertibles in connection with the issue may only be made based on publicly available information regarding the Company and its securities. Failure to comply with these instructions may constitute a violation of the Securities Act or applicable laws in other jurisdictions.

Forward-Looking Statements

This press release contains forward-looking statements that relate to the Company’s intentions, assessments or expectations regarding the Company’s future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the fact that they contain expressions such as “believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “assumes”, “should” “could” and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no guarantee that they will occur or that they are correct. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements. Such risks, uncertainties, contingencies and other material factors may cause the actual course of events to differ materially from the expectations expressly or implicitly stated in this press release through the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct and each reader of the press release should not unduly rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressly or implicitly stated herein are provided only as of the date of this press release and may change. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that exist regarding the content of this press release, unless required by law.

The following attachments are available for download: